Clinical implications of the inhibition of the late sodium current: a new paradigm in the treatment of ischaemic heart disease 

Br J Cardiol 2008;15(Suppl 1):S2 Leave a comment
Click any image to enlarge
Sponsorship Statement: This supplement is supported by CV Therapeutics Europe Ltd. It may contain information on uses outside the approved Summary of Product Characteristics (SmPC) for ranolazine. CV Therapeutics does not recommend the use of ranolazine in any other manner than as described in the Summary of Product Characteristics. CVTE/CORP/00115

A symposium, sponsored by CV Therapeutics Europe Ltd, was held during the British Cardiovascular Society (BCS) meeting in Manchester on 2 June 2008. This report is a summary of the symposium.

Advertisement
Heart failure - BJC Learning programme
For healthcare professionals only

Introduction

Angina is a common, debilitating and unrelenting condition which takes its toll on individuals both in their leisure and occupational life and which can impose a significant financial burden on the health services of a nation.

Opening the meeting, Co-Chair, Professor John Camm (St George’s Hospital, London) described the new antianginal compound, ranolazine. Whilst the mechanism of action of ranolazine is largely unknown, it may have some antianginal effects by inhibition of the late sodium current in cardiac cells. This reduces intracellular sodium accumulation and consequently decreases intracellular calcium overload. Ranolazine, via its action to decrease the late sodium current, is considered to reduce these intracellular ionic imbalances during ischaemia. This reduction in cellular calcium overload is expected to improve myocardial relaxation and thereby decrease left ventricular diastolic stiffness. Symptoms of angina are improved.

Ranolazine is available in the US and has recently received approval from the European Medicines Agency (EMEA). Ranolazine can be used in the EU as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies such as beta blockers and calcium antagonists.

Sponsorship statement

This supplement is supported by CV Therapeutics Europe Ltd. It may contain information on uses outside the approved Summary of Product Characteristics (SmPC) for ranolazine. CV Therapeutics does not recommend the use of ranolazine in any other manner than as described in the Summary of Product Characteristics. CVTE/CORP/00115 (Located in the PDF download).

Disclaimer: UK prescribing information current at the date of publication of this supplement can be found by downloading the PDF. Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.
THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT